SABLE: A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without Benlysta (Belimumab) (116543)First published 16/10/2013 Last updated 10/02/2025 EU PAS number: EUPAS4966StudyOngoing